A 55 year-old man with unstable angina is treated with an intravenously administered glycoprotein IIb – IIIa inhibitor. The mechanism of action of this agent is the ability to.
**Core Concept**
Glycoprotein IIb-IIIa inhibitors are a class of antiplatelet drugs that play a crucial role in the management of acute coronary syndromes, including unstable angina. These agents work by inhibiting the final common pathway of platelet aggregation, which is essential for thrombus formation.
**Why the Correct Answer is Right**
Glycoprotein IIb-IIIa inhibitors bind to the glycoprotein IIb-IIIa receptor on the surface of activated platelets, thereby preventing the binding of fibrinogen and other ligands. This action effectively blocks the platelet aggregation process, which is mediated by the glycoprotein IIb-IIIa receptor. The inhibition of platelet aggregation reduces the risk of thrombus formation and subsequent ischemic events in patients with unstable angina.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because glycoprotein IIb-IIIa inhibitors do not work by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of thromboxane A2 and prostaglandins.
**Option B:** Incorrect because glycoprotein IIb-IIIa inhibitors do not primarily act by increasing the production of nitric oxide (NO), although NO may have a role in vasodilation and platelet inhibition.
**Option C:** Incorrect because glycoprotein IIb-IIIa inhibitors do not work by blocking the action of thrombin, which is a key enzyme in the coagulation cascade.
**Option D:** Incorrect because glycoprotein IIb-IIIa inhibitors do not primarily act by inhibiting the platelet-activating factor (PAF), which is involved in platelet activation and aggregation.
**Clinical Pearl / High-Yield Fact**
It's essential to remember that glycoprotein IIb-IIIa inhibitors are typically used in conjunction with aspirin and heparin in the management of acute coronary syndromes. The combination of these agents can significantly reduce the risk of ischemic events and improve patient outcomes.
**Correct Answer: D. Inhibiting platelet aggregation by blocking the glycoprotein IIb-IIIa receptor.**